Royal Bank of Canada’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $198K | Sell |
3,837
-3,150
| -45% | -$160K | ﹤0.01% | 4724 |
|
|
2025
Q4 | $346K | Buy |
6,987
+355
| +5% | +$17.3K | ﹤0.01% | 4434 |
|
|
2025
Q3 | $316K | Sell |
6,632
-14,837
| -69% | -$597K | ﹤0.01% | 4798 |
|
|
2025
Q2 | $677K | Buy |
21,469
+9,800
| +84% | +$314K | ﹤0.01% | 4231 |
|
|
2025
Q1 | $382K | Buy |
11,669
+4,729
| +68% | +$168K | ﹤0.01% | 4195 |
|
|
2024
Q4 | $250K | Buy |
6,940
+1,016
| +17% | +$35.8K | ﹤0.01% | 4629 |
|
|
2024
Q3 | $184K | Buy |
5,924
+463
| +8% | +$14.4K | ﹤0.01% | 4880 |
|
|
2024
Q2 | $145K | Buy |
5,461
+1,421
| +35% | +$41.2K | ﹤0.01% | 5016 |
|
|
2024
Q1 | $138K | Sell |
4,040
-11,588
| -74% | -$345K | ﹤0.01% | 4996 |
|
|
2023
Q4 | $451K | Buy |
15,628
+8,134
| +109% | +$216K | ﹤0.01% | 4359 |
|
|
2023
Q3 | $208K | Buy |
7,494
+2,802
| +60% | +$85.3K | ﹤0.01% | 4768 |
|
|
2023
Q2 | $141K | Buy |
4,692
+410
| +10% | +$14.3K | ﹤0.01% | 5059 |
|
|
2023
Q1 | $154K | Sell |
4,282
-4,821
| -53% | -$185K | ﹤0.01% | 4838 |
|
|
2022
Q4 | $325K | Buy |
9,103
+5,304
| +140% | +$184K | ﹤0.01% | 4471 |
|
|
2022
Q3 | $129K | Buy |
3,799
+2,335
| +159% | +$76K | ﹤0.01% | 5137 |
|
|
2022
Q2 | $42K | Sell |
1,464
-2,663
| -65% | -$76.3K | ﹤0.01% | 5796 |
|
|
2022
Q1 | $133K | Sell |
4,127
-4,893
| -54% | -$150K | ﹤0.01% | 5438 |
|
|
2021
Q4 | $262K | Buy |
9,020
+3,195
| +55% | +$96.9K | ﹤0.01% | 5071 |
|
|
2021
Q3 | $156K | Buy |
5,825
+1,334
| +30% | +$35.8K | ﹤0.01% | 5388 |
|
|
2021
Q2 | $138K | Buy |
4,491
+1,833
| +69% | +$56.2K | ﹤0.01% | 5384 |
|
|
2021
Q1 | $69K | Sell |
2,658
-18,097
| -87% | -$506K | ﹤0.01% | 5686 |
|
|
2020
Q4 | $522K | Buy |
20,755
+159
| +0.8% | +$3.42K | ﹤0.01% | 4097 |
|
|
2020
Q3 | $429K | Sell |
20,596
-277
| -1% | -$6.29K | ﹤0.01% | 3991 |
|
|
2020
Q2 | $496K | Sell |
20,873
-308
| -1% | -$6.8K | ﹤0.01% | 3774 |
|
|
2020
Q1 | $381K | Buy |
21,181
+19,297
| +1,024% | +$406K | ﹤0.01% | 3848 |
|
|
2019
Q4 | $44K | Sell |
1,884
-569
| -23% | -$13.8K | ﹤0.01% | 5512 |
|
|
2019
Q3 | $67K | Sell |
2,453
-24,780
| -91% | -$734K | ﹤0.01% | 5003 |
|
|
2019
Q2 | $901K | Sell |
27,233
-169
| -0.6% | -$5.79K | ﹤0.01% | 3392 |
|
|
2019
Q1 | $960K | Buy |
27,402
+1,891
| +7% | +$70.4K | ﹤0.01% | 3228 |
|
|
2018
Q4 | $848K | Sell |
25,511
-488
| -2% | -$21K | ﹤0.01% | 3295 |
|
|
2018
Q3 | $1.31M | Sell |
25,999
-3,275
| -11% | -$162K | ﹤0.01% | 3169 |
|
|
2018
Q2 | $1.75M | Buy |
29,274
+4,903
| +20% | +$254K | ﹤0.01% | 2828 |
|
|
2018
Q1 | $1.12M | Buy |
24,371
+551
| +2% | +$23K | ﹤0.01% | 3090 |
|
|
2017
Q4 | $948K | Sell |
23,820
-2,326
| -9% | -$91.9K | ﹤0.01% | 3269 |
|
|
2017
Q3 | $1.05M | Sell |
26,146
-245,305
| -90% | -$10.6M | ﹤0.01% | 3187 |
|
|
2017
Q2 | $11.7M | Buy |
271,451
+240,978
| +791% | +$8.58M | 0.01% | 1414 |
|
|
2017
Q1 | $954K | Buy |
30,473
+222
| +0.7% | +$5.95K | ﹤0.01% | 3123 |
|
|
2016
Q4 | $764K | Buy |
30,251
+9,776
| +48% | +$218K | ﹤0.01% | 3381 |
|
|
2016
Q3 | $506K | Buy |
20,475
+1,339
| +7% | +$30.3K | ﹤0.01% | 3700 |
|
|
2016
Q2 | $390K | Sell |
19,136
-2,810
| -13% | -$49.8K | ﹤0.01% | 3903 |
|
|
2016
Q1 | $335K | Buy |
21,946
+9,104
| +71% | +$119K | ﹤0.01% | 3972 |
|
|
2015
Q4 | $173K | Buy |
12,842
+2,206
| +21% | +$34.1K | ﹤0.01% | 4620 |
|
|
2015
Q3 | $149K | Sell |
10,636
-869
| -8% | -$16.2K | ﹤0.01% | 4523 |
|
|
2015
Q2 | $196K | Buy |
+11,505
| New | +$164K | ﹤0.01% | 4380 |
|
|
2014
Q4 | – | Sell |
-20,781
| Closed | -$181K | – | 6285 |
|
|
2014
Q3 | $181K | Sell |
20,781
-4,887
| -19% | -$44.1K | ﹤0.01% | 4258 |
|
|
2014
Q2 | $281K | Buy |
+25,668
| New | +$229K | ﹤0.01% | 3916 |
|
|
2013
Q3 | – | Sell |
-10
| Closed | – | – | 6247 |
|
|
2013
Q2 | $0 | Buy |
+10
| New | +$59 | ﹤0.01% | 5848 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Royal Bank of Canada's SUPN Position: Q1 2026 in Review
Royal Bank of Canada reduced its Supernus Pharmaceuticals (SUPN) stake by 45% in Q1 2026, selling an estimated $160K and leaving 3,837 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #4724.
Royal Bank of Canada first reported a position in SUPN in Q2 2013 and has held it in 47 quarters since. The position peaked at $11.7M in Q2 2017. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Royal Bank of Canada held 3,837 shares of Supernus Pharmaceuticals worth $198K as of Q1 2026.
- Royal Bank of Canada sold 3,150 Supernus Pharmaceuticals shares in Q1 2026, an estimated $160K.
- Supernus Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4724 holding.
- Royal Bank of Canada first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Royal Bank of Canada's Supernus Pharmaceuticals position peaked at $11.7M in Q2 2017.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.